Thank you for attending the BASL Annual Meeting 2025. We hope that you found the event both informative and enjoyable

 

In order to continue to improve our events we would be grateful if you could complete this short feedback survey

 

Many thanks

BASL Event Managers

Skin Cancer post transplant - Ferina Ismail

1 = Poor - 5 = Excellent

Epidemiology of Cancer after solid Organ Transplantation (the EpCOT study) - Professor Adnan Sharif

1 = Poor - 5 = Excellent

Recurrent PSC post-transplant - Dr Deepak Joshi

1 = Poor - 5 = Excellent

SpR Case presentation -TBC

1 = Poor - 5 = Excellent

Post-transplant biliary strictures – results of national Audit - Jess Dyson & Mohammed Elseragy

1 = Poor - 5 = Excellent

MDT approach to biliary strictures post-transplant – radiology, endoscopy surgery and hep - Jonathan Potts

SpR Case presentation – assessing the comorbid patient - Jennifer Gallacher

1 = Poor - 5 = Excellent

Assessing and modifying perioperative risk - Dr Suehana Rahman

1 = Poor - 5 = Excellent

From Survival to Sustainability: Cardiovascular Longevity After Liver Transplant - Associate Prof Lisa Van Wagner

1 = Poor - 5 = Excellent

Working Together on Fatigue in PBC: Practical Multiprofessional Approaches

1 = Poor - 5 = Excellent

BASL and Frontline gastroenterology - a match made in Hepatology - Dr Tim Cross & Phil Smith

1 = Poor - 5 = Excellent

Burden of liver disease in IBD - Dr Richard Howard

1 = Poor - 5 = Excellent

Surveillance in IBD and PSC - Dr Omar Sherriff

1 = Poor - 5 = Excellent

Finding an effective treatment for PSC - Professor Michael Trauner

1 = Poor - 5 = Excellent

Optimising nutrition in IBD/PSC - Brigid McCue

1 = Poor - 5 = Excellent

New options for patients with IBD and liver disease pre and post liver transplant - Professor Glen Doherty

1 = Poor - 5 = Excellent

Dame Sheila Sherlock presentation - Paul Brennan

1 = Poor - 5 = Excellent

Leveraging success in HCV elimination to tackle current challenges in HBV & HDV

1 = Poor - 5 = Excellent

Advancing the Management of MASH: Drivers of Disease, Guidelines, and Clinical Insights

1 = Poor - 5 = Excellent

Not an oncologist? Join us to explore how hepatologists can navigate the role of immunotherapy in hepatocellular carcinoma (HCC) within the multidisciplinary team.

1 = Poor - 5 = Excellent

Improving HCC Surveillance in the UK - Professor Stuart McPherson

1 = Poor - 5 = Excellent

Data and learning from the national HCC programme - Michèle Bourke

The Role of Radiotherapy in Primary Liver Cancer - Professor Aisling Barry

1 = Poor - 5 = Excellent

British liver update - Vanessa Hebditch

1 = Poor - 5 = Excellent

Inequalities in health care and its impact on liver disease cancer - Professor Joanne Morling

1 = Poor - 5 = Excellent

Dietetics: Thomas Crame

1 = Poor - 5 = Excellent

Exercise: Dr Kate Hallsworth

1 = Poor - 5 = Excellent

Therapeutics: Dr Robert Elliot Cooke

1 = Poor - 5 = Excellent

Metabolic/therapeutic approaches: Prof Jeremy Tomlinson

1 = Poor - 5 = Excellent

Psychologist: Prof Leah Avery

1 = Poor - 5 = Excellent

Surgery/L: Professor Helen Heneghan

1 = Poor - 5 = Excellent

Bariatric CNS: Dr Claire Kearney

1 = Poor - 5 = Excellent

A Metabolic Spotlight on MASH

1 = Poor - 5 = Excellent

The (re)evolution in genetic cholestasis - Professor Richard Thompson

1 = Poor - 5 = Excellent

Introducing and delivering new therapies in PBC - Arron Jones

1 = Poor - 5 = Excellent

Mechanisms and new approaches - Dr Maria Londono

1 = Poor - 5 = Excellent

thinking outside the box

1 = Poor - 5 = Excellent

The prevalence of liver cirrhosis and its associated complications among patients with hereditary haemochromatosis in England (PREDISPOSE HEME) - Dr Prabhsimran Singh

1 = Poor - 5 = Excellent

Implementing a nurse-led early discharge clinic for patients with decompensated chronic liver disease to reduce readmission rates and length of hospital stay - Liliana Goncalves King

1 = Poor - 5 = Excellent

Evaluation of the acceptability and effectiveness of assistant psychologist-led Screening, Brief Intervention and Referral to Treatment (SBIRT) within Hillingdon Hospital alcohol pathway - O3

1 = Poor - 5 = Excellent

Development and validation of dimethylarginines (DAS) as a novel biomarker to identify pre-ACLF and predict outcomes following acute decompensation of cirrhosis in two prospective multicentre European cohorts - Dr Kohilan Gananandan

1 = Poor - 5 = Excellent

24-month clinical outcomes of a therapeutic stepwise approach involving low-dose systemic thrombolysis for managing acute portomesenteric thrombosis - Dr Aqib Chowdhury

1 = Poor - 5 = Excellent

Differential liver transplant delivery across socioeconomic strata in individuals presenting acutely to hospital with chronic liver disease in England - Dr Cori Campbell

1 = Poor - 5 = Excellent

Discovery the evolving landscape of primary sclerosing cholangitis (PSC)

1 = Poor - 5 = Excellent

Industry Symposium Gilead

1 = Poor - 5 = Excellent

Working smarter in Hepatology - Dr Ankur Srivastava

1 = Poor - 5 = Excellent

New tech = better outcomes? - Dr Johnny Cash

1 = Poor - 5 = Excellent

The role of the FMT - Professor Debbie Shawcross

1 = Poor - 5 = Excellent

Ready For Prime Time? -Dr Martin James

1 = Poor - 5 = Excellent

A nurse-led, one-stop-shop approach to MASLD assessment, risk stratification and patient education: the Belfast experience - Leanne Stratton

1 = Poor - 5 = Excellent

Linerixibat significantly improves cholestatic pruritus in primary biliary cholangitis (PBC): results of the pivotal Phase 3 GLISTEN trial -

1 = Poor - 5 = Excellent

Efficacy and Safety of Third-Line Therapies in Autoimmune Hepatitis: Short- and Long-Term Outcomes from a Real-World Cohort - Dr Llkay Ergenc

1 = Poor - 5 = Excellent

Multimodal liver assessment with Endoscopic Ultrasound-guided Portosystemic Pressure Gradient (EUS-PPG), EUS-liver biopsy & variceal screening: A single centre experience - Dr Martin James

1 = Poor - 5 = Excellent

Haemochromoatosis - Prof John Ryan

1 = Poor - 5 = Excellent

Liver disease in cystic fibrosis - Dr Emer Fitzpatrick

1 = Poor - 5 = Excellent

Vascular liver diseases - Dr David Patch

1 = Poor - 5 = Excellent

Prehabilitation in patients with liver disease - Suzanne Lester

1 = Poor - 5 = Excellent

Please rate the overall quality of the BASL Annual Meeting

1 = Poor - 5 = Excellent

Please rate the overall quality of the sessions

1 = Poor - 5 = Excellent

would you consider attending another BASL annual meeting?

If no, why not?

Do you think the registration fee was value for money for the meeting?

If you answered No, why not?

Was there anything that was particularly good?

What could be improved

Thank You
We are using a temporary cookie to streamline your experience. No personal data is stored and the cookie is removed once you complete your registration.

Your Browser Settings have Cookies Disabled

This site requires a temporary cookie to streamline your experience. No personal data is stored and the cookie will be removed once you complete your registration. Please enable cookies in your browser and refresh this page.